Literature DB >> 22260662

Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.

Mari Gotoh1, Yuko Fujiwara, Junming Yue, Jianxiong Liu, SueChin Lee, James Fells, Ayako Uchiyama, Kimiko Murakami-Murofushi, Stephen Kennel, Jonathan Wall, Renukadevi Patil, Renuka Gupte, Louisa Balazs, Duane D Miller, Gabor J Tigyi.   

Abstract

LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22260662      PMCID： PMC3590848          DOI： 10.1042/BST20110608

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN： 0300-5127            Impact factor:   5.407


  50 in total

1.  Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines.

Authors:  Nicole Euer; Marina Schwirzke; Vesna Evtimova; Helmut Burtscher; Michael Jarsch; David Tarin; Ulrich H Weidle
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

2.  Plasma lysophosphatidic acid concentration and ovarian cancer.

Authors:  Daniel L Baker; Patton Morrison; Brigitte Miller; Caroline A Riely; Betsy Tolley; Anneke M Westermann; Johannes M G Bonfrer; Evert Bais; Wouter H Moolenaar; Gabor Tigyi
Journal:  JAMA       Date:  2002-06-19       Impact factor: 56.272

3.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Authors:  T B Pustilnik; V Estrella; J R Wiener; M Mao; A Eder; M A Watt; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Specific increase in serum autotaxin activity in patients with pancreatic cancer.

Authors:  Yousuke Nakai; Hitoshi Ikeda; Kazuhiro Nakamura; Yukio Kume; Mitsuhiro Fujishiro; Naoki Sasahira; Kenji Hirano; Hiroyuki Isayama; Minoru Tada; Takao Kawabe; Yutaka Komatsu; Masao Omata; Junken Aoki; Kazuhiko Koike; Yutaka Yatomi
Journal:  Clin Biochem       Date:  2011-03-31       Impact factor: 3.281

5.  Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase.

Authors:  Akira Tokumura; Eiji Majima; Yuko Kariya; Kyoko Tominaga; Kentaro Kogure; Katsuhiko Yasuda; Kenji Fukuzawa
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

6.  Lysophospholipids are potential biomarkers of ovarian cancer.

Authors:  Rebecca Sutphen; Yan Xu; George D Wilbanks; James Fiorica; Edward C Grendys; James P LaPolla; Hector Arango; Mitchell S Hoffman; Martin Martino; Katie Wakeley; David Griffin; Rafael W Blanco; Alan B Cantor; Yi-jin Xiao; Jeffrey P Krischer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-07       Impact factor: 4.254

Review 7.  The emerging role of lysophosphatidic acid in cancer.

Authors:  Gordon B Mills; Wouter H Moolenaar
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

8.  Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.

Authors:  Padma Murthi; Gillian Barker; Cameron J Nowell; Gregory E Rice; Mark S Baker; Bill Kalionis; Michael A Quinn
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

9.  Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.

Authors:  M L Stracke; H C Krutzsch; E J Unsworth; A Arestad; V Cioce; E Schiffmann; L A Liotta
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

10.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.

Authors:  Makiko Umezu-Goto; Yasuhiro Kishi; Akitsu Taira; Kotaro Hama; Naoshi Dohmae; Koji Takio; Takao Yamori; Gordon B Mills; Keizo Inoue; Junken Aoki; Hiroyuki Arai
Journal:  J Cell Biol       Date:  2002-07-15       Impact factor: 10.539
View more
  39 in total

1.  Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Jianxiong Liu; Junming Yue; Yoshibumi Shimizu; Derek D Norman; Yaohong Wang; Ryoko Tsukahara; Erzsebet Szabo; Renukadevi Patil; Souvik Banerjee; Duane D Miller; Louisa Balazs; Manik C Ghosh; Christopher M Waters; Tamas Oravecz; Gabor J Tigyi
Journal:  Mol Cancer Res       Date:  2014-08-26       Impact factor: 5.852

2.  Allergic to autotaxin. A new role for lysophospholipase d and lysophosphatidic Acid in asthma?

Authors:  Steve N Georas
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

3.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

4.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

Review 5.  The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.

Authors:  Sara Knowlden; Steve N Georas
Journal:  J Immunol       Date:  2014-02-01       Impact factor: 5.422

6.  The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.

Authors:  Ji Hee Ha; Jeremy D Ward; Lakshmi Varadarajalu; Sang Geon Kim; Danny N Dhanasekaran
Journal:  Cell Signal       Date:  2013-09-19       Impact factor: 4.315

Review 7.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

8.  Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.

Authors:  James I Fells; Sue Chin Lee; Yuko Fujiwara; Derek D Norman; Keng Gat Lim; Ryoko Tsukahara; Jianxiong Liu; Renukadevi Patil; Duane D Miller; R Jason Kirby; Sandra Nelson; William Seibel; Ruben Papoian; Abby L Parrill; Daniel L Baker; Robert Bittman; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2013-06-21       Impact factor: 4.436

9.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

10.  Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.

Authors:  Ingun Heiene Tveteraas; Monica Aasrum; Ingvild Johnsen Brusevold; John Ødegård; Thoralf Christoffersen; Dagny Sandnes
Journal:  Tumour Biol       Date:  2015-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.